Fermentek

Fermentek is an Israeli biotechnology company founded in 1994 by Dr. Yosef Behrend. Based in Jerusalem’s Atarot industrial zone, the company researches, develops, and manufactures biologically active natural products isolated from microorganisms and other natural sources, including plants and algae. Its production platform relies primarily on nonpathogenic actinomycetes, including Nocardia and Streptomyces species, together with fungi such as Penicillium, Aspergillus, and Fusarium. The company states that the organisms it uses are not human pathogens. Fermentek’s business is directed mainly toward professional and institutional customers rather than individual consumers. A substantial share of its products is distributed through major international chemical distributors, often under distributor-owned brands. This channel-oriented model gives the company a relatively low-profile market presence while allowing its compounds and reference materials to reach laboratories, analytical testing organizations, pharmaceutical researchers, and biotechnology developers in multiple countries. The company has particular importance in the mycotoxin market. Mycotoxins are toxic substances produced by molds and can contaminate food and animal feed, creating public-health, regulatory, and agricultural risks. Fermentek manufactures a broad range of purified mycotoxins for use as analytical standards in food and feed testing. Its product range includes aflatoxins, fumonisins, zearalenone, deoxynivalenol, trichothecenes, patulin, citrinin, gliotoxin, and several toxins associated with Alternaria and other fungi. The company has stated that it supplies the worldwide requirement for at least one specialized compound, Aflatoxin M2, although the supplied reference material does not provide a date or quantitative market share for that claim. In 2009, Fermentek introduced FermaSol, a family of standardized calibrant solutions containing important mycotoxins. These solutions were intended to support more consistent calibration and quantification in analytical laboratories. In 2010, Fermentek obtained ISO 13485 accreditation in connection with producing starting materials for experimental drug production and reference standards for food contaminants. Fermentek also produces immunomodulators, ionophores, specialized antibiotics, molecular-biology reagents, and compounds used in experimental drug research. Examples include tacrolimus, sirolimus, ascomycin, myriocin, valinomycin, nonactin, ionomycin, anisomycin, wortmannin, staurosporine, bafilomycin, oligomycin, trichostatin A, rapamycin, thapsigargin, cyclopamine, geldanamycin derivatives, and other biologically active molecules. These offerings are generally research materials or starting materials rather than finished medicines for direct patient use. The company emphasizes a classical biotechnology approach. According to the referenced description of its policy, Fermentek uses naturally occurring, genetically unmodified microbial strains and does not deliberately create mutant strains through random or targeted methods. Its fermentation infrastructure includes fermentors ranging from 10 to 15,000 liters, supported by filter presses and centrifuges of corresponding capacity. Fermentek moved into a new building in 2004. The relocation reportedly quadrupled its working space and substantially expanded manufacturing capacity. The company’s stated commercial objective is not to discover or invent new compounds, but to make known natural products more affordable and accessible to the scientific community. Its identity therefore combines industrial fermentation, specialty chemical manufacturing, analytical reference-material production, and supply of research compounds for life-sciences laboratories.

Fermentek was established in Israel in 1994 by Dr. Yosef Behrend. From its origins, the company was organized around the production of biologically active natural substances obtained through microbial fermentation and related extraction processes. Rather than positioning itself as a developer of original pharmaceutical inventions, Fermentek focused on manufacturing known compounds and supplying them at prices intended to make them more accessible to the scientific community. Its production system uses nonpathogenic actinomycetes, including Nocardia and Streptomyces, as well as fungi from genera such as Penicillium, Aspergillus, and Fusarium. The company describes this as a classical biotechnology model based on naturally occurring, genetically unmodified strains. The approach excludes deliberate creation of random or targeted mutants. Fermentek’s industrial equipment includes fermentors with capacities from 10 to 15,000 liters, together with filter presses and centrifuges designed for comparable processing volumes. A major stage in the company’s development came in 2004, when it moved to a new building in Jerusalem’s Atarot industrial zone. The facility reportedly provided four times the previous working space and enabled a substantial increase in manufacturing capacity. The expansion supported a broader portfolio of microbial natural products and improved the company’s ability to serve international distributors and professional users. Fermentek became particularly associated with purified mycotoxins. These compounds are produced by molds and may contaminate human food and animal feed. Accurate reference materials are required by food-safety laboratories and other analytical organizations to identify and quantify contamination. Fermentek developed an extensive catalogue of purified mycotoxins, including aflatoxins, fumonisins, zearalenone, deoxynivalenol, patulin, citrinin, gliotoxin, trichothecenes, and compounds associated with Alternaria and other molds. The company has been described as supplying the global requirement for Aflatoxin M2, though the available material does not establish the precise extent or duration of that position. In 2009, Fermentek announced FermaSol, a product family of highly standardized calibrant solutions for principal mycotoxins. The launch addressed the need for consistent, ready-to-use calibration materials in contaminant analysis. In 2010, the company obtained ISO 13485 accreditation relating to starting materials for experimental drug production and reference standards for food contaminants. This accreditation marked a formal quality milestone for two of its technically regulated areas. Beyond mycotoxins, Fermentek’s portfolio includes immunomodulators such as tacrolimus, sirolimus, ascomycin, and myriocin; ionophores such as valinomycin, nonactin, and ionomycin; and a wide assortment of antibiotics and molecular-biology reagents. It also supplies compounds used in experimental drug research, including rapamycin, parthenolide, thapsigargin, cyclopamine, staurosporine, wortmannin, geldanamycin derivatives, and other research chemicals. These products serve laboratories and industrial intermediaries rather than retail consumers. The company generally reaches customers through international chemical distributors, many of which market the products under their own brands. This means Fermentek’s manufacturing role may be less visible than that of downstream catalog brands, even when its compounds enter research, analytical, or pharmaceutical workflows. The available references do not provide detailed information about later ownership, leadership, revenue, geographic sales breakdown, or current corporate structure. Fermentek is nevertheless characterized as an Israeli biotechnology manufacturer with an enduring specialization in fermentation-derived natural products and analytical standards.

1. 2010ISO 13485 accreditation obtained

   Fermentek obtained ISO 13485 accreditation relating to experimental-drug starting materials and reference standards for food contaminants.

   Source
2. 2009FermaSol calibrant solutions announced

   The company introduced FermaSol, a family of standardized calibrant solutions for major mycotoxins.

   Source
3. 2004Move to an expanded Atarot facility

   Fermentek moved to a new building in Jerusalem’s Atarot industrial zone. The facility reportedly quadrupled its working space and expanded manufacturing capacity.

   Source
4. 1994Fermentek is founded

   Dr. Yosef Behrend founded Fermentek in Israel to manufacture biologically active natural products derived primarily from microorganisms.

   Source

A specialist biotechnology and research-chemicals manufacturer focused on affordable, standardized natural products, mycotoxin reference materials, and biologically active compounds for professional laboratories and industrial customers.

• Mycotoxin reference standardsAnalytical reference materials

  Fermentek produces purified mycotoxins for use as analytical standards in food, feed, and contaminant testing. The range includes aflatoxins, fumonisins, zearalenone, deoxynivalenol, patulin, citrinin, gliotoxin, trichothecenes, and several Alternaria-associated compounds. These materials help laboratories calibrate instruments and verify methods for detecting mold-derived toxins.

• FermaSolMycotoxin calibrant solutions2009

  FermaSol is a family of standardized calibrant solutions for important mycotoxins. It was introduced to provide analytical laboratories with more consistent calibration materials for quantitative contaminant testing.

• ImmunomodulatorsResearch compounds

  The immunomodulator portfolio includes compounds such as tacrolimus, sirolimus, ascomycin, and myriocin. These are supplied as research materials for laboratory and pharmaceutical investigations rather than as finished medicines for individual patients.

• IonophoresResearch compounds

  Fermentek lists ionophores including valinomycin, nonactin, and ionomycin. Such compounds are used in biochemical, cellular, and pharmacological research involving ion transport and membrane processes.

• Experimental drug and research compoundsDrug-research materials

  The company supplies natural products and related molecules used in experimental drug research, including rapamycin, parthenolide, thapsigargin, cyclopamine, staurosporine, wortmannin, midostaurin, geldanamycin, and geldanamycin derivatives such as 17-AAG and 17-DMAG.

• 2009Launch of the FermaSol calibrant-solution familyProduct launch

  Analytical laboratories require standardized materials to calibrate instruments and quantify mycotoxin contamination.

  What changed. Fermentek announced a family of standardized calibrant solutions for major mycotoxins under the FermaSol name.

  Aftermath. The launch broadened Fermentek’s offering beyond purified compounds into prepared analytical calibration products. The available reference does not provide sales or adoption data.

  Source
• 2004Expansion through relocation to a larger facilityStrategy

  Growing production requirements called for greater working space and manufacturing capacity.

  What changed. Fermentek moved into a new Atarot facility that reportedly quadrupled its working space and expanded production capacity.

  Aftermath. The move provided the infrastructure for larger-scale fermentation and broader natural-product manufacturing.

  Source

• 2010Fermentek obtains ISO 13485 accreditation

  The company obtained ISO 13485 accreditation associated with producing starting materials for experimental drug production and reference standards for food contaminants.

  Regulation
  Source
• 2009Fermentek announces the FermaSol calibrant-solution product family

  Fermentek announced a family of standardized calibrant solutions for major mycotoxins, extending its reference-material offering for analytical laboratories.

  Product launch
  Source

1. Fermentek